Trials / Completed
CompletedNCT04167280
Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- University of Saskatchewan · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study is looking at the development of tolerance to methacholine following regular use of ipratropium bromide in mild asthmatics.
Detailed description
This study is being conducted people with well controlled (mild) asthma to determine if ipratropium bromide taken three times daily for six days (i.e. 2 puffs in the morning, 2 puffs in the afternoon and 2 puffs in the evening) followed by a final dose on the morning of day 7 reduces the effectiveness of this medication on blocking the effect of methacholine challenge.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ipratropium Metered Dose Inhaler | MDI to deliver 20mcg per puff ipratropium bromide |
| DRUG | placebo metered dose inhaler | matched MDI to deliver inactive drug |
Timeline
- Start date
- 2019-11-05
- Primary completion
- 2020-03-13
- Completion
- 2020-03-13
- First posted
- 2019-11-18
- Last updated
- 2020-03-26
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04167280. Inclusion in this directory is not an endorsement.